St. Jude Children's Research Hospital

Ting Therapeutics LLC

Tal Teitz

Jian Zuo

Taosheng Chen

Jaeki Min

R Kiplin Guy

Jill M Lahti

Vincent J Kidd

Fei Zheng

Tetsuji Yamashita

Jie Fang

Fang Jie

Goktug Asli

Min Jaeki

Chen Taosheng

Zoe Kellard

Asli Goktug

In one aspect, pharmaceutical compositions comprising a CDK2 inhibitor and one or more of at least one agent known to treat a hearing impairment and at least one agent known to prevent a hearing impairment, and methods of treating and/or preventing hearing impairments or disorders using the compositions are disclosed. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Methods and compositions for the prevention and treatment of hearing loss

Oseltamivir is used as active agent to treat a hearing impairment and to prevent a hearing impairment, and a method of treating and/or preventing hearing impairments or disorders using Oseltamivir are disclosed. Oseltamivir exhibits excellent protection against noise-induced hearing loss and against cisplatin-induced hearing loss.

Methods for the prevention and treatment of hearing loss using Oseltamivir

Methods and compositions using an inhibitor of EGFR signaling for prevention or an inhibitor of EGFR signaling and a nucleic acid molecule encoding an atonal-associated factor for treatment of hearing loss are described.

Compositions and methods for prevention and treatment of hearing loss

The present invention relates to identification of tumor suppressor activity of a protein, caspase-8 (CASP8), and to related diagnostic and therapeutic compositions and methods. The discovery of this tumor suppressor activity provides screening targets as well, particularly screening for compounds that overcome gene inactivation that results from genomic methylation of the promoter. In particular, CASP8 is functionally inactivated in greater than 90% of all MYCN amplified neuroblastoma cell lines analyzed. Inactivation of CASP8 was observed to occur by homozygous deletion, heterozygous deletion coupled with gene silencing by methylation, and homozygous gene silencing by methylation. A PCR methylation analysis for inactivation of CASP8 is described.

Tumor suppressor protein involved in death signaling, and diagnostics, therapeutics, and screening based on this protein

Growing community of inventors

Cordova, TN, United States of America

Tal Teitz